cefotaxime sandoz
sandoz new zealand limited - cefotaxime sodium 1048.2mg equivalent to 1000 mg cefotaxime; - powder for injection - 1000 mg - active: cefotaxime sodium 1048.2mg equivalent to 1000 mg cefotaxime
cefotaxime sandoz
sandoz new zealand limited - cefotaxime sodium 2096.4mg equivalent to 2000 mg cefotaxime; - powder for injection - 2000 mg - active: cefotaxime sodium 2096.4mg equivalent to 2000 mg cefotaxime
cefotaxime sandoz
sandoz new zealand limited - cefotaxime sodium 524.1mg equivalent to 500 mg cefotaxime; - powder for injection - 500 mg - active: cefotaxime sodium 524.1mg equivalent to 500 mg cefotaxime
curam
sandoz new zealand limited - amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml; ; potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage); ; - powder for oral suspension - 125mg,31.25mg/5ml - active: amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage) excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.
curam
sandoz new zealand limited - amoxicillin trihydrate 287mg equivalent to amoxycillin 250 mg; ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg - film coated tablet - 250mg/125mg - active: amoxicillin trihydrate 287mg equivalent to amoxycillin 250 mg potassium clavulanate 149mg equivalent to clavulanic acid 125 mg excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.
curam duo 500/125
sandoz new zealand limited - amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg; ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg; - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg potassium clavulanate 149mg equivalent to clavulanic acid 125 mg excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.
rivaroxaban sandoz
sandoz new zealand limited - rivaroxaban 10mg; - film coated tablet - 10 mg - active: rivaroxaban 10mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 04f530012 sodium laurilsulfate - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.
rivaroxaban sandoz
sandoz new zealand limited - rivaroxaban 15mg; - film coated tablet - 15 mg - active: rivaroxaban 15mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 04f530006 sodium laurilsulfate - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.
rivaroxaban sandoz
sandoz new zealand limited - rivaroxaban 20mg; - film coated tablet - 20 mg - active: rivaroxaban 20mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 04f530010 sodium laurilsulfate - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.
foradil
sandoz new zealand limited - formoterol fumarate 12ug - powder filled inhalation capsule - 12 mcg - active: formoterol fumarate 12ug excipient: gelatin ink lactose monohydrate - foradil is indicated for the treatment of bronchoconstriction in adults and children six years of age and over with asthma as an add-on to inhaled corticosteroid (ics) treatment. in the management of asthma, foradil should be used only as an adjunct to corticosteroids. foradil should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.